Lilly receives positive CHMP opinion for Jaypirca in CLL
Lilly (NYSE:LLY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Jaypirca (pirtobrutinib) in adults with chronic lymphocytic leukemia (CLL).





-2-640x358.webp&w=3840&q=75)




